Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases.
Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases.
复制标题
DOI：
--
复制
发表时间：
2000-04
期刊：
影响因子：
--
通讯作者：
G. Lakos;E. Kiss;N. Regéczy;P. Tarján;P. Soltész;M. Zeher;E. Bodolay;G. Szücs;S. Szakony;S. Sipka;G. Szegedi
中科院分区：
文献类型：
--
作者：
G. Lakos;E. Kiss;N. Regéczy;P. Tarján;P. Soltész;M. Zeher;E. Bodolay;G. Szücs;S. Szakony;S. Sipka;G. Szegedi
目的探讨自身免疫性疾病患者抗凝血酶原（aPT）和抗膜联蛋白V（aANX）自身抗体IgG同种型与血栓形成的关系。比较这些抗体与抗心磷脂 (aCL)、抗 β2-糖蛋白 I 抗体（抗 β2-GPI）和狼疮抗凝物 (LAC) 的临床相关性。方法 采用固相酶联免疫分析法测定 70 例全身性自身免疫性疾病患者、35 例抗磷脂综合征 (APS) 患者和 35 例无 APS 患者的血清 IgG aPT、aANX、aCL 和抗 β2-GPI 水平。分析医疗记录，并评估抗体与 APS 临床特征的关联。结果 与无 APS 的患者相比，APS 患者的 aPT (p = 0.001) 和 aANX (p = 0.002) 频率较高。患有 aPT 或 aANX 的患者比没有患 aPT 或 aANX 的患者更容易发生血栓事件（分别为 p = 0.005、p = 0.006）。发现 aPT 和 aANX 的存在对于 APS 具有高度特异性。结论 aPT和aANX抗体的检测可能对确诊APS以及评估全身性自身免疫性疾病患者静脉和动脉血栓形成的风险具有重要价值。
OBJECTIVE To investigate the relationship between antiprothrombin (aPT) and antiannexin V (aANX) autoantibodies of IgG isotype and thrombosis in patients with systemic autoimmune diseases. To compare the clinical relevance of these antibodies to that of anticardiolipin (aCL), anti-beta2-glycoprotein I antibodies (anti-beta2-GPI), and lupus anticoagulant (LAC). METHODS Serum IgG aPT, aANX, aCL, and anti-beta2-GPI levels were measured by solid phase enzyme immunoassay in the sera of 70 patients with systemic autoimmune diseases, 35 with antiphospholipid syndrome (APS) and 35 without APS. Medical records were analyzed, and associations of the antibodies with clinical features of APS were assessed. RESULTS Patients with APS had higher frequency of aPT (p = 0.001) and aANX (p = 0.002) compared to patients without APS. Thrombotic events occurred more frequently in those with aPT or aANX than those without (p = 0.005, p = 0.006, respectively). The presence of aPT and aANX was found to be highly specific for APS. CONCLUSION Measurement of aPT and aANX antibodies may be of value in confirming the diagnosis of APS, and in evaluating risk of venous and arterial thrombosis in patients with systemic autoimmune diseases.